High-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’ enters Mongolia in a matter of time
Mongolian Minister of Health and Welfare Sodnom Chinzorig makes a surprise visit to AdipoLABs
CEO Han Sung-ho “We will provide maximum support to donate and introduce REMISSION 1℃.”
Mongolian Minister of Health and Welfare Sodnom Chinzorig (left) and AdipoLABs CEO Han Sung-ho (right)
【Health and Welfare News】 The Minister of Health and Welfare of Mongolia made a surprise visit to AdipoLABs Co., Ltd., the company that is delivering new hope to cancer patients around the world with the high-frequency hyperthermia cancer treatment device 'REMISSION 1℃'. Both signed an agreement for treatment. This will be a bridgehead for advancing into Mongolian market.
AdipoLABs Co., Ltd. (CEO Han Sung-ho), a manufacturer of high-frequency hyperthermia cancer treatment devices that have been proven to be effective in Korea is receiving tremendous attention from the medical community through successful clinical treatment cases at international academic seminars. On the 15th, the Minister of Health and Welfare of Mongolia Sodnom Chinzorig paid a visit to the company and announced that they had signed an agreement on bringing 'REMISSION 1℃' to Mongolia.
The international academic seminar was held by AdipoLABs Co., Ltd., a company sponsored by IVRA (co-representatives Sung-ho Han, Seung-mo Yoo, chairman Hong-seok Jang), which has been providing high-frequency hyperthermia cancer therapy device 'REMISSION 1℃' to each IVRA member country for the purpose of cancer treatment and clinical trials. As a result of the continued export and donation of the device, the Mongolian Ministry of Health and Welfare has also become interested.
In particular, Minister Sodnom Chinzorig expressed interest in introducing ‘REMISSION 1℃’ at the national cancer center in his country and announced that he would work to obtain permission for the introduction of the cancer treatment device in Mongolia.
He also requested cooperation from domestic medical staff and related associations to treat cancer patients in his country through ‘REMISSION 1℃’.
Accordingly, CEO Han Sung-ho promised to provide maximum support so that the Mongolian government can introduce a high-frequency hyperthermia cancer treatment device better. Han decided to donate the first ‘REMISSION 1℃’ for the Mongolian government’s domestic approval and clinical trials.
CEO Han Sung-ho said, “The proven effectiveness of ‘REMISSION 1℃’ shown at the IVRA International Conference is delivering a message of hope to patients around the world who are heavily suffering from a disease of cancer.” He added, “High-frequency hyperthermia treatment is also available in Mongolia for cancer patients.” “I expect REMISSION 1℃ to be in the right place for Mongolian patients.” he said.
In addition, Mongolian Minister of Health and Welfare Sodnom Chinzorig's visit to AdipoLABs is evaluated as an opportunity to further raise the status of Korean medical technology.
 High-frequency hyperthermia cancer treatment device
‘REMISSION 1℃’ Meanwhile, IVRA (International Virus Research Alliance) is a medical association formed in response to COVID pandemic and is making academic progress with each successive meeting. Currently, there are about 200 members at home and abroad, and they are taking a lead in setting the direction for future cancer treatment by sharing professional knowledge on post-COVID cancer treatment and holding related seminars every year. Minister Sodnom Chinzorig promised that Mongolian medical staff will also participate in the IVRA International Conference to be held at St. Mary's Hospital in Seoul on June 9th. |
